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dan321@126.comAbstract A fast, simple and sensitive high performance liquid chromatographic (HPLC) method has
been developed for determination of 10a-methoxy-6-methyl ergoline-8b-methanol (MDL, a main
metabolite of nicergoline) in human plasma. One-step liquid–liquid extraction (LLE) with diethyl ether
was employed as the sample preparation method. Tizanidine hydrochloride was selected as the internal
standard (IS). Analysis was carried out on a Diamonsil ODS column (150 mm 4.6 mm, 5 mm) using
acetonitrile–ammonium acetate (0.1 mol/L) (15/85, v/v) as mobile phase at detection wavelength of
224 nm. The calibration curves were linear over the range of 2.288–73.2 ng/mL with a lower limit of
quantitation (LLOQ) of 2.288 ng/mL. The intra- and inter-day precision values were below 13% and
the recoveries were from 74.47% to 83.20% at three quality control levels. The method herein described
was successfully applied in a randomized crossover bioequivalence study of two different nicergoline
preparations after administration of 30 mg in 20 healthy volunteers.
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(D. Zhang).1. Introduction
Nicergoline (10a-methoxy-1,6-dimethylergoline-8b-methanol-
5-bromonicotinat), a semisynthetic ergoline derivative with
a-adrenergic blocking [1] and vasodilating activities, has been
clinically used for improving the brain metabolism and treating
cerebrovascular disorders and senile mental impairment [2].
Pharmacokinetic and metabolic studies [3,4] have shown that
nicergoline is rapidly absorbed and extensively metabolized to
1-methyl-10a-methoxy-9, 10-dihydrolysergol (MMDL) after oral
administration, which is further N-demethylated to form 10a-
methoxy-9,10-dihydrolysergol (MDL) as the main metabolite.
Consequently, almost no nicergoline could be detected in human
plasma and pharmacokinetic studies of nicergoline have been
mainly based on the determination of MDL. To our knowledge,
some methods, such as radioimmunoassay [5,6], HPLC–UV [7,8]
An HPLC–UV method for determination of MDL and its application in bioequivalence study 63and HPLC–MS [9–11], have been used for the determination of
nicergoline and its metabolite MDL in biological matrixes.
This paper described a simple, rapid and sensitive HPLC–UV
method for the determination of MDL in human plasma. An
LLOQ of 2.288 ng/mL was achieved and the sample preparation
was simple involving a single liquid–liquid extraction with diethyl
ether. This method was validated and applied in a randomized
crossover bioequivalence study, following oral administration of
two different nicergoline preparations in 20 healthy volunteers.2. Experimental
2.1. Chemicals and materials
MDL (purity 92.47%, by HPLC peak area normalization
method) was obtained from IVAX Pharmaceuticals s.r.o (Cˇesko).
Tizanidine hydrochloride (purity 99.8%) used as internal stan-
dard (IS) was supplied by YS Company (Sichuan, China).
Acetonitrile (HPLC grade) was provided by Honeywell Interna-
tional Incorporated (Muskegon, KL, USA). Other chemicals
were all of analytical grade. Double-distilled water, prepared from
demineralized water, was used throughout the study.
2.2. Preparation of standard and quality control samples
Stock solutions of MDL and IS were prepared by dissolving
the accurately weighed standards in methanol and double-
distilled water to concentrations of 91.5 mg/mL and 2.00 mg/mL,
respectively. The stock solution of MDL was then appropriately
diluted with methanol to obtain working standard solutions at
seven concentrations of 0.0572, 0.1144, 0.2288, 0.4575, 0.915,
1.3725 and 1.83 mg/mL, and the IS stock solution was also diluted
in double-distilled water to the concentrations of 0.0625, 0.125,
0.25, 0.5, 1 and 1.5 mg/mL. All the solutions were stored at 4 1C.
The calibration standard samples were prepared by spiking
working standard solution (20 mL) of MDL into 500 mL blank
plasma to give concentrations of 2.288, 4.576, 9.152, 18.3, 36.6,
54.9 and 73.2 ng/mL. Quality control (QC) samples were gener-
ated with the same process to yield ﬁnal concentrations of 4.576,
18.3 and 54.9 ng/mL. All spiked samples were then extracted as
the sample preparation procedure described below.
2.3. Preparation of plasma samples
To a 500 mL aliquot of plasma thawed at room temperature,
20 mL of IS solution (1.00 mg/mL), 10 mg sodium ﬂuoride (NaF)
and 0.2 mL sodium hydroxide (5 mol/L) were added. The
mixture was vortexed for 1 min and extracted with 2.5 mL of
diethyl ether by vortex mixing for 10 min and centrifugation at
3000 rpm for 5 min. The upper organic layer was transferred into
another set of clean glass tubes and evaporated to dryness at
40 1C under a gentle stream of air. The residue was reconstituted
in 70 mL of mobile phase, followed by vortexing and centrifuga-
tion at 3000 rmp for 5 min. An aliquot of 20–50 mL supernatant
was injected into the HPLC system.
2.4. Apparatus and chromatographic condition
An LC-10A liquid chromatograph (Shimadzu, Kyoto, Japan)
was used in this study. The system comprised a pump (LC-10A),a manual injector, a column oven and a UV–VIS spectro-
photometric detector (SPD-10A). The HPLC system was con-
trolled with Chromtek chromatography workstation (Version
5.3; Alltech, USA). The HPLC separation was carried out on a
Diamonsil ODS column (150 mm 4.6 mm, 5 mm) with the
detector operated at 224 nm. The mobile phase composed of
acetonitrile-0.1 M ammonium acetate (15:85, v/v) was delivered
at a ﬂow rate of 1.0 mL/min. The column oven temperature was
set at 30 1C.
2.5. Pharmacokinetic application
The present method was applied in a randomized crossover
equivalence study of two capsule formulations of nicergoline
in twenty healthy male volunteers (aging 18–28 years; body
mass index 19–24) following single oral administration of
30 mg nicergoline capsule from either SN pharmaceutical
company (Harbin, China) or Ethypharm pharmaceutical Co.
Ltd. (EPC, France). Venous blood samples were collected into
heparinized tubes immediately before administration and at
the following times after dosing: 1, 2, 2.5, 3, 3.5, 4, 4.5, 6, 9,
12, 16 and 30 h. Plasma samples were obtained by centrifuga-
tion of whole blood and stored at 20 1C until analysis. After
1 week wash-out period the subjects were crossed-over.3. Results and discussion
3.1. Selection of internal standard
A proper IS should possess similar characteristics for extrac-
tion, chromatography and detection as the analyte, and be
well resolved from all other chromatographic peaks. There-
fore, two compounds, tizanidine hydrochloride and azasetron
hydrochloride, had been tried as IS for their similar structures
with MDL. Tizanidine hydrochloride was preliminarily chosen
as IS for its similarity to MDL in polarity, retention time and
extraction efﬁciency.
Further investigation was developed to evaluate the corre-
lation of recovery between the MDL and IS. 20 mL working
standard solutions of MDL with concentration range of
0.0572–1.83 mg/mL were evaporated, respectively, in seven
glass tubes under gentle stream of air at 40 1C. After addition
of 500 mL human blank plasma and 20 mL IS at the corre-
sponding concentration range of 0.0625–2 mg/mL, the samples
spiked in duplicates were then extracted as described in
Section 2.3. The measured concentrations and recoveries of
MDL and IS were calculated based on the standard curves,
respectively. As a result, the recoveries of MDL and IS were
highly correlated with a correlation coefﬁcient (r) of 0.85, and
tizanidine hydrochloride was selected as IS ﬁnally.
3.2. Optimization of the extraction
Since MDL is liposoluble and has low concentration in
plasma, liquid–liquid extraction is applied to isolate MDL
from other substances in human plasma samples. Six govern-
ing parameters: extraction solvent (trichlormethane, ethyl
acetate, diethyl ether and methyl tert–butyl ether), extraction
volume (2, 2.5 and 3 mL), alkalizer volume (0.1, 0.2 and
0.3 mL, 5 mol/L), alkalizer concentration (0.5, 2.5, 5 and
6 mol/L, 0.1 mL), equilibrium time (0, 5, 15 and 30 min) and
R. Zheng et al.64enzyme inhibitor (0, 5, 10 and 15 mg) were optimized by the
univariate approach. According to the experiment, diethyl
ether and methyl tert–butyl ether both gained good recoveries
with no interference and diethyl ether was ﬁnally selected as
the extraction solvent for its lower price and temperature to
evaporate. The addition of proper (0.2 mL, 5 mol/L) sodium
hydroxide solution could shift MDL and the IS to their non-
ionized forms and improve the extraction recovery. No
equilibrium time was required because MDL could bind to
the plasma protein immediately after being added into plasma;
however, some NaF were necessary as enzyme inhibitor to
protect the drug from metabolism in vitro. As a result, MDL
was found to be exhaustively extracted with 2.5 mL diethyl
ether, 0.2 mL sodium hydroxide of 5 mol/L, 10 mg NaF and
without equilibrium time.
3.3. Validation of the method
3.3.1. Selectivity and speciﬁcity
Typical chromatograms of human blank plasma, blank plasma
spiked with MDL and IS, and plasma samples obtained after
drug administration are shown in Fig. 1. Under optimized
chromatographic conditions, no interferences were found at
the retention time of MDL (8.28070.34 min) and IS (6.8837
0.49 min).
3.3.2. Linearity and LLOQ
Calibration curves were obtained by assaying standard plasma
samples at seven concentration levels in the range of 2.288–
73.2 ng/mL with least squares linear regression. The linearity
was determined by plotting the peak-area ratios (y) of MDL to
IS versus the nominal concentration (x) of MDL. Linear
regression equation was y¼2.83 102xþ0.41 102 with
correlation coefﬁcient (r) of 0.9990. The LLOQ for MDL
was 2.288 ng/mL.Figure 1 Typical chromatograms of a blank human plasma (A), a bla
plasma samples obtained at 3 h after single oral dose of two nicergoline
1, IS; 2, MDL.3.3.3. Extraction recovery
The extraction recovery of MDL from plasma was determined
at three QC levels by comparing peak areas (n¼5, at each
concentration) extracted from plasma with those obtained
from the same amounts of unextracted solutions. The recov-
eries of MDL at three concentration levels were 70.47%,
83.20% and 81.09%, respectively.
3.3.4. Precision and accuracy
The intra-day precision and accuracy were calculated by
quintet quantitation of MDL at three QC levels on the same
day, and inter-day precision and accuracy by repeated analysis
on three different days (n¼5 series per day). The measured
concentrations of MDL were calculated based on linearity
plots. The precision was assessed by values of the relative
standard deviation (RSD), while the accuracy by relative error
(RE), and the results are summarized in Table 1. In both
situations, the RSD values and RE were all less than 15%,
which was considered to be acceptable according to the
guidance of State Food and Drug Administration (SFDA).
3.3.5. Stability
The short-term (at room temperature for 8 h), long-term (at
20 1C for 45 days), three freeze-thaw cycles and post-
treatment (in the reconstituted extract at room temperature
for 9 h) stability had been evaluated by analyzing replicates
(n¼3) at three QC levels. The data of stabilities are shown in
Table 2. No signiﬁcant change in the concentration of MDL
was found under the condition described previously.
3.4. Application in bioequivalence study
The method described above had been successfully used for
determination of MDL in plasma in a randomized crossovernk plasma spiked with MDL (18.3 ng/mL) and IS (B), and human
capsules (C for test preparation and D for reference preparation).
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Figure 2 Mean plasma concentrations vs. time proﬁles of MDL
in 20 healthy volunteers following a single oral dose of 30 mg of
test (SN, ) and reference (EPC, m) preparations.
Table 1 Precision and accuracy of MDL in plasma.
Spiked
concentration
(ng/mL)
Intra-day precision (n¼5) Inter-day precision (n¼5)
Measured
concentration
(mean7SD)
RE (%) RSD
(%)
Measured
concentration
(mean7SD)
RE (%) RSD
(%)
4.576 4.2870.53 6.5 12.5 4.4870.43 2.1 12.5
18.300 17.0670.82 6.8 4.9 17.2671.04 5.7 6.1
54.900 49.6872.84 9.5 5.8 55.6573.77 1.4 7.7
Table 2 Stability of MDL in plasma.
Spiked concentration
(ng/mL)
Short-term stability Long-term stability Freeze and thaw stability Post-preparation stability
Mean7SD RSD
(%)
Mean7SD RSD
(%)
Mean7SD RSD
(%)
Mean7SD RSD
(%)
4.576 4.270.1 2.7 4.570.3 7.2 4.570.4 9.9 4.570.3 5.8
18.3 16.470.1 0.6 17.671.0 5.7 17.671.2 6.6 17.170.2 1.4
54.9 51.472.3 4.6 54.872.0 3.7 53.771.8 3.5 51.671.9 3.8
Table 3 The pharmacokinetic parameters of nicergoline
for two preparations in 20 healthy volunteers after admin-
istration of a single 30 mg oral dose (Mean7SD).
Parameter Test Reference P valuea
T1/2 (h) 8.42771.217 9.30571.797 NS
Tmax (h) 3.40070.417 3.30070.479 NS
Cmax (ng/mL) 34.504710.231 32.851710.869 NS
AUC0t
[ng/(h mL)]
353.752767.617 340.047764.966 NS
AUC0N
[ng/(h mL)]
388.380766.735 382.912762.208 NS
T1/2: elimination half time; Tmax: time to maximum concentra-
tion; Cmax: maximum concentration; AUC0t: area under the
plasma concentration–time curve from 0 h to the last concentra-
tion observed; AUC0N: area under the plasma concentration–
time curve from 0 h to inﬁnity.
aNS, no signiﬁcant difference (Po0.05).
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30 mg of two different nicergoline preparations in 20 healthy
volunteers. The mean plasma concentration of MDL versus
time curves for both preparations are shown in Fig. 2.
Pharmacokinetic parameters were calculated by DAS 2.1.1
statistical software (Pharmacology Institute of China) and
resulted pharmacokinetic parameters are summarized in
Table 3. The values of the 90.0% conﬁdence intervals for
Cmax, AUC0t and AUC0N were 99.1–112.7%, 99.2–108.7%
and 97.0–105.5%, respectively, which all fell within the range
of 75–133% and 80.0–125.0% deﬁned by the SFDA. These
observations conﬁrm the bioequivalence of the test sample
with the reference product in terms of rate and absorption.4. Conclusion
A simple, rapid and accurate method has been developed and
validated for the determination of MDL, a metabolite ofnicergoline, in human plasma using the HPLC method with
UV detection. The method, which is rapid with run time of
10 min and sensitive with LLOQ of 2.288 ng/mL, has been
demonstrated to be suitable for human pharmacokinetic studies
of nicergoline.References
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